文献速递眼底病与葡萄膜炎

阿柏西普按需治疗糖尿病黄斑水肿的长期结局:ENDURANCE扩展研究2年结果

Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
PubMed 文献 · Br J Ophthalmol · 2017-08-16

ENDURANCE为IV期开放标签2年扩展研究,纳入完成3年VISTA DME试验的60例患者,按疾病活动度个体化给予2.0 mg玻璃体腔注射阿柏西普。2年内平均注射7.7次,25%患者无需再治疗,48%患者注射≤5次;VISTA期视力与中心视网膜厚度获益维持稳定,但10%患眼进展为增殖性糖尿病视网膜病变。

要点

  • 2年内平均注射阿柏西普7.7次,25%患者无需再治疗,48%患者注射≤5次。
  • VISTA期获得的视力与中心视网膜厚度获益在ENDURANCE期间维持稳定。
  • 10%(6例)患眼从非增殖性转为增殖性糖尿病视网膜病变,共8例发生PDR事件。

核心结论

  • 在VISTA DME试验启动治疗后,第4和第5年DME患者对阿柏西普再治疗的需求大幅减少。
  • 3年VISTA DME试验获得的视力获益在ENDURANCE期间以较低治疗负担得以维持,但观察到临床相关的糖尿病视网膜病变恶化,10%患眼进展为PDR。

研究设计与样本

  • IV期、2年、开放标签扩展研究,纳入完成3年VISTA DME III期试验的60例患者。
  • 所有患者在存在临床相关DME时接受阿柏西普治疗,访视间隔根据疾病活动度设定。
  • 主要结局指标为2年内平均阿柏西普注射次数。

主要发现

  • 2年内平均注射阿柏西普7.7次。
  • 15例(25%)患者无需再治疗,48%(n=29)患者2年内注射≤5次。
  • 在ENDURANCE期间接受至少1次阿柏西普再治疗的患者中,2年内平均注射9.5次。
  • VISTA DME期间获得的平均视力和中心视网膜厚度增益在ENDURANCE期间维持稳定。
  • 最显著的安全性信号为糖尿病视网膜病变进展:6例(10%)从非增殖性转为增殖性糖尿病视网膜病变(PDR),共8例发生PDR事件,发生于前次阿柏西普治疗后平均387天。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To evaluate the efficacy and safety of individualised 2.0 mg intravitreal aflibercept retreatment for diabetic macular oedema (DME) through the fifth year of management. METHODS: This is a phase IV, 2-year, open-label extension study. Sixty patients completing the 3-year VISTA DME (Study of Intravitreal Aflibercept Injection in Patients With Diabetic Macular Edema) phase III trial enrolled in the ENDURANCE (Long-Term Efficacy and Safety of Intravitreal Aflibercept for the Treatment of DME in Subjects Who Completed the VISTA DME Trial) extension study. All patients received aflibercept in the presence of clinically relevant DME. Intervals between visits were prescribed according to disease activity. The main outcome measure was mean aflibercept injections given through 2 years. RESULTS: A mean of 7.7 aflibercept injections were administered through 2 years. Fifteen (25%) patients required no retreatment and 48% (n=29) of patients received five or fewer injections through 2 years. Among patients who received at least one aflibercept retreatment during ENDURANCE, the mean number of injections through 2 years was 9.5. The mean visual acuity and central retinal thickness gains achieved during VISTA DME were maintained and stable during ENDURANCE. The most notable safety signal was progression of diabetic retinopathy. Six (10%) patients converted from non-proliferative to proliferative diabetic retinopathy (PDR), and a total of eight patients experienced PDR events occurring at a mean of 387 days following the previous aflibercept treatment. CONCLUSION: The need for aflibercept retreatment was substantially reduced in the fourth and fifth years of aflibercept dosing for DME following initiation of therapy in the VISTA DME trial. While vision gains achieved during the 3-year VISTA DME trial were maintained through ENDURANCE with a reduced treatment burden, clinically relevant worsening of diabetic retinopathy was observed with progression to PDR in 10% of the eyes. TRIAL REGISTRATION NUMBER: NCT02299336.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Wykoff CC, Ou WC, Khurana RN, et al. Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study. Br J Ophthalmol. 2017. PMID: 28814412. doi:10.1136/bjophthalmol-2017-310941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。